33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Al-Ahmadie, H.; Brannon, A. R.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Opioid safety among high-risk cancer survivors
    Meeting Abstract

    Salz, T.; Mishra, A. A.; Gennarelli, R. L.; Lipitz-Snyderman, A.; Boudreau, D.; Moryl, N.; Tringale, K. R.; Korenstein, D.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer
    Meeting Abstract

    Romesser, P. B.; Holliday, E. B.; Philip, T.; Sarholz, B.; Kuipers, M.; Rodriguez-Gutierrez, A.; Diaz-Padilla, I.; Miller, E. D.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
    Meeting Abstract

    Rugo, H. S.; Llombart-Cussac, A.; Andre, F.; Robson, M. E.; Saji, S.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Ahn, J. S.; Nanda, R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Chronic opioid therapy among a high-risk cancer survivor population
    Meeting Abstract

    Salz, T.; Lavery, J. A.; Lipitz-Snyderman, A.; Boudreau, D.; Moryl, N.; Gillespie, E. F.; Korenstein, D.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • HLA genotyping in synovial sarcoma: Identifying HLA-A*02 and its association with clinical outcome
    Meeting Abstract

    Rosenbaum, E.; Seier, K.; Bandlamudi, C.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Movva, S.; Nacev, B.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for malignant pleural mesothelioma (MPM) (NRG LU-006)
    Meeting Abstract

    Rimner, A.; Zauderer, M. G.; Yorke, E.; Simone, C. B.; Gill, R. R.; Voong, K. R.; Peikert, T.; Tsao, M. S.; Li, Z.; Rusch, V. W.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2-positive metastatic pancreatic cancer (mPC)
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Furuse, J.; Kunieda, F.; Jie, F.; Kindler, H. L.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Adoption patterns of an electronic patient-reported outcomes tool in oncology
    Meeting Abstract

    Polubriaginof, F. C. G.; Parekh, P. K.; Akella, N. R. S.; Stetson, P. D.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A genomic blood test (NETest) identifies neuroendocrine transformation of prostate cancer
    Meeting Abstract

    Rahbar, K.; Kidd, M. S.; Drozdov, I. A.; Malczewska, A.; Bodei, L.; Rajwa, P.; Boegemann, M.; Bernemann, C.; Kitz, A.; Modlin, I. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save